- Previous Close
2.0900 - Open
2.0800 - Bid 2.0400 x --
- Ask 2.0500 x --
- Day's Range
2.0300 - 2.0800 - 52 Week Range
1.6600 - 2.6600 - Volume
77,600 - Avg. Volume
82,870 - Market Cap (intraday)
2.676B - Beta (5Y Monthly) 0.78
- PE Ratio (TTM)
12.00 - EPS (TTM)
0.1700 - Earnings Date --
- Forward Dividend & Yield 0.18 (8.68%)
- Ex-Dividend Date Jul 2, 2024
- 1y Target Est
--
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, together with its subsidiaries, produces and sells traditional Chinese medicine, western medicine, and other products primarily in the People's Republic of China. The company manufactures and sells of biochemical pharmaceutical products. It also engages in research and development of chinese patent medicines, chemical raw materials and preparations, and nutritional supplements. In addition, the company is involved in pharmaceutical and drug retail business. Further, it offers Suxiao Jiuxin pills, Qingyan drop pills, Jingwanhong ointment, Angong Niuhuang pills, Qingfei pills, anti-inflammatory pills, Qinggong Shoutao pills, Biqi capsules, Niuhuang Qingxin pills, Tongmai Yangxin pills, and Weichang An pills. Additionally, the company pharmaceutical logistic services. Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited was formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited and changed its name to Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited in May 2022. The company was founded in 1981 and is based in Tianjin, the People's Republic of China.
www.jydrt.com.cn4,619
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: T14.SI
View MorePerformance Overview: T14.SI
Trailing total returns as of 1/10/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: T14.SI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: T14.SI
View MoreValuation Measures
Market Cap
2.68B
Enterprise Value
2.65B
Trailing P/E
12.36
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.43
Price/Book (mrq)
1.79
Enterprise Value/Revenue
2.42
Enterprise Value/EBITDA
17.76
Financial Highlights
Profitability and Income Statement
Profit Margin
11.60%
Return on Assets (ttm)
4.69%
Return on Equity (ttm)
14.18%
Revenue (ttm)
8.04B
Net Income Avi to Common (ttm)
932.37M
Diluted EPS (ttm)
0.1700
Balance Sheet and Cash Flow
Total Cash (mrq)
1.5B
Total Debt/Equity (mrq)
19.87%
Levered Free Cash Flow (ttm)
-214.5M